Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran.
Department of Medical Basic Sciences, Khoy University of Medical Sciences, Khoy, Iran.
J Glob Antimicrob Resist. 2024 Mar;36:466-472. doi: 10.1016/j.jgar.2023.10.025. Epub 2023 Nov 20.
The neuraminidase (NA) mutations causing resistance to NA inhibitors (NAIs) mostly compromise the fitness of influenza viruses. Considering the importance of these mutations, constant monitoring of the effectiveness of available drugs is critical. This study aimed to identify NA mutations in the influenza A/H1N1 and A/H3N2 subtypes in the samples of Mazandaran, Iran from 2016 to 2020.
In this cross-sectional study, 20 influenza A/H1N1 and 20 influenza A/H3N2 samples were included in the study. After design of appropriate primers for NA gene, all samples subjected to RT-PCR and electrophoresis. Then the PCR product was sequenced to determine the mutations.
In the present study, no oseltamivir resistance-related mutations were detected. Still, NA gene showed variations compared to the vaccine strains. In A/H1N1, a total of 43 mutations were detected. Similarly, in A/H3N2, a total of 66 mutations were observed. In all isolates of H1N1, N200S, N248D and I321V mutations were detected in the antigenic site of NA protein, which can affect vaccine incompatibility and virus escape from the host's immune system. Also, H150R mutation was observed in the NA active site of H3N2, which is the cause of agglutination by NA protein. Also, S245N mutation was identified as a new N-Glycosylation site of H3N2 subtype.
The study of NA gene sequences revealed no oseltamivir resistance mutations. In H1N1 isolates, ca. 97% identities and in the H3N2 subtype, 96% identities were observed compared to reference isolate of 2009, which indicates the importance of constant monitoring of the emergence of the drug resistance mutations.
导致抗流感神经氨酸酶抑制剂(NAI)耐药的神经氨酸酶(NA)突变大多会损害流感病毒的适应性。鉴于这些突变的重要性,持续监测现有药物的有效性至关重要。本研究旨在确定 2016 年至 2020 年伊朗马赞达兰省流感 A/H1N1 和 A/H3N2 亚型的 NA 突变。
在这项横断面研究中,将 20 份流感 A/H1N1 和 20 份流感 A/H3N2 样本纳入研究。在为 NA 基因设计适当的引物后,所有样本均进行 RT-PCR 和电泳。然后对 PCR 产物进行测序以确定突变。
在本研究中,未检测到与奥司他韦耐药相关的突变。尽管如此,与疫苗株相比,NA 基因仍存在变异。在 A/H1N1 中,共检测到 43 种突变。同样,在 A/H3N2 中,共观察到 66 种突变。在所有 H1N1 分离株中,在 NA 蛋白的抗原结合部位检测到 N200S、N248D 和 I321V 突变,这可能影响疫苗不匹配和病毒逃避宿主免疫系统。此外,在 H3N2 的 NA 活性部位观察到 H150R 突变,这是 NA 蛋白凝集的原因。此外,S245N 突变被鉴定为 H3N2 亚型的新 N-糖基化位点。
NA 基因序列研究未发现奥司他韦耐药突变。在 H1N1 分离株中,与 2009 年参考分离株相比,约 97%的同一性,在 H3N2 亚型中,96%的同一性,这表明持续监测耐药突变的出现非常重要。